Active, not recruitingPhase 3NCT04498117
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Studying Primary peritoneal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CanariaBio Inc.
- Principal Investigator
- Sunil Gupta, MD, FRCPCCanariaBio Inc.
- Intervention
- Oregovomab(biological)
- Enrollment
- 615 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2020 – 2028
Study locations (30)
- Honor Health, Phoenix, Arizona, United States
- The University of Arizona Cancer Center, Tucson, Arizona, United States
- John Muir Health Clinical Research Center, Concord, California, United States
- Kaiser Permanente Southern California, Irvine, California, United States
- Moores UC San Diego Cancer Center, La Jolla, California, United States
- Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
- Epic Care, Pleasant Hill, California, United States
- Kaiser Permanente Riverside Medical Center, Riverside, California, United States
- University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
- Contra Costa Oncology, Walnut Creek, California, United States
- John Muir Health Gynecologic Cancer Services, Walnut Creek, California, United States
- University of Colorado Health, Aurora, Colorado, United States
- University of Connecticut Health Center, Farmington, Connecticut, United States
- Smilow Cancer Hospital, New Haven, Connecticut, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Gynecologic Oncology Group · Iqvia Pty Ltd
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04498117 on ClinicalTrials.govOther trials for Primary peritoneal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07480954Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07322094CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian CancerTORL Biotherapeutics, LLC
- RECRUITINGPHASE3NCT06915025Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerImunon
- RECRUITINGPHASE2NCT07023484Personalized Timing of Interval Debulking Surgery in Advanced Ovarian CancerThe University of Hong Kong
- RECRUITINGPHASE2NCT06639074Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT TrialMayo Clinic
- RECRUITINGPHASE1NCT06469281A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRegeneron Pharmaceuticals
- RECRUITINGPHASE2NCT06492070Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological CancersEmory University
- RECRUITINGPHASE2NCT06434610A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.Shanghai Jiaolian Drug Research and Development Co., Ltd